HRMY
Harmony·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Strong Buy"
MACD Golden Cross
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HRMY
Harmony Biosciences Holdings, Inc.
A pharmaceutical company focused on therapies for rare neurological diseases
Pharmaceutical
07/25/2017
08/19/2020
NASDAQ Stock Exchange
268
12-31
Common stock
630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462
--
Harmony Biosciences Holdings, Inc., founded on July 25, 2017, is a commercial-stage pharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with rare neurological diseases with unmet medical needs. The company's product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action, or MOA, specifically designed to enhance histamine signaling in the brain by binding to H3 receptors.
Company Financials
EPS
HRMY has released its 2025 Q3 earnings. EPS was reported at 1.08, versus the expected 0.74, beating expectations. The chart below visualizes how HRMY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HRMY has released its 2025 Q3 earnings report, with revenue of 239.46M, reflecting a YoY change of 28.71%, and net profit of 50.87M, showing a YoY change of 10.35%. The Sankey diagram below clearly presents HRMY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
